During the past decade, Edinburgh Cancer Research Centre conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 4 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Edinburgh Cancer Research Centre" #1 sponsor was "Aprea Therapeutics" with 2 trials, followed by "AstraZeneca" with 2 trials sponsored, "Agalimmune Ltd." with 1 trials sponsored, "BioNTech SE" with 1 trials sponsored and "CCTU- Cancer Theme" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Edinburgh Cancer Research Centre" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Edinburgh Cancer Research Centre" are "Advanced Ovarian Cancer" (1 trials), "BRCA Mutated" (1 trials), "BRCA Mutation" (1 trials), "Complete Response" (1 trials) and "Extensive-stage Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Edinburgh Cancer Research Centre" in a lesser frequency.

Most popular intervention types in "Edinburgh Cancer Research Centre" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "APR-246" (2 trials), "Olaparib 300mg tablets" (2 trials), "AGI-134" (1 trials), "Abraxane (nab-paclitaxel)" (1 trials) and "Amrubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Edinburgh Cancer Research Centre" are 4 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Edinburgh Cancer Research Centre". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Edinburgh Cancer Research Centre, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Edinburgh Cancer Research Centre, 3 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".